BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 31077539)

  • 1. Prospective evaluation of gadoxetic acid magnetic resonance for the diagnosis of hepatocellular carcinoma in newly detected nodules ≤2 cm in cirrhosis.
    Ayuso C; Forner A; Darnell A; Rimola J; García-Criado Á; Bianchi L; Vilana R; Oliveira R; Llarch N; Bruix J
    Liver Int; 2019 Jul; 39(7):1281-1291. PubMed ID: 31077539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study.
    Granito A; Galassi M; Piscaglia F; Romanini L; Lucidi V; Renzulli M; Borghi A; Grazioli L; Golfieri R; Bolondi L
    Aliment Pharmacol Ther; 2013 Feb; 37(3):355-63. PubMed ID: 23199022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.
    Rimola J; Forner A; Sapena V; Llarch N; Darnell A; Díaz A; García-Criado A; Bianchi L; Vilana R; Díaz-González Á; Ayuso C; Bruix J; Reig M
    Eur Radiol; 2020 Jan; 30(1):186-194. PubMed ID: 31372783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid.
    Semaan S; Vietti Violi N; Lewis S; Chatterji M; Song C; Besa C; Babb JS; Fiel MI; Schwartz M; Thung S; Sirlin CB; Taouli B
    Eur Radiol; 2020 Feb; 30(2):1020-1030. PubMed ID: 31673837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features?
    Joo I; Lee JM; Lee DH; Jeon JH; Han JK
    Eur Radiol; 2019 Apr; 29(4):1724-1732. PubMed ID: 30255250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
    Lee MH; Kim SH; Park MJ; Park CK; Rhim H
    AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of indeterminate hepatocellular nodules at Gd-EOB-DPTA-enhanced MRI in cirrhotic patients.
    Galia M; Agnello F; Sparacia G; Matranga D; Albano D; Midiri M; Lagalla R
    Radiol Med; 2018 Jul; 123(7):489-497. PubMed ID: 29546493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Portal hypertension may influence the registration of hypointensity of small hepatocellular carcinoma in the hepatobiliary phase in gadoxetic acid MR.
    Caparroz C; Forner A; Rimola J; Darnell A; García-Criado Á; Ayuso JR; Reig M; Bruix J; Ayuso C
    Radiol Oncol; 2022 Aug; 56(3):292-302. PubMed ID: 35776837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focal lesions in the cirrhotic liver: their pivotal role in gadoxetic acid-enhanced MRI and recognition by the Western guidelines.
    Golfieri R; Garzillo G; Ascanio S; Renzulli M
    Dig Dis; 2014; 32(6):696-704. PubMed ID: 25376286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of adding hepatobiliary phase image in magnetic resonance imaging for detection of hepatocellular carcinoma: a meta-analysis.
    Pan J; Li W; Gu L; Liu C; Zhang K; Hong G
    Eur Radiol; 2022 Nov; 32(11):7883-7895. PubMed ID: 35579711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis.
    Park MJ; Kim YK; Lee MH; Lee JH
    Acta Radiol; 2013 Mar; 54(2):127-36. PubMed ID: 23148300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining the Arterial Phase of Contrast-Enhanced Ultrasonography, Gadoxetic Acid-Enhanced Magnetic Resonance Imaging and Diffusion-Weighted Imaging in the Diagnosis of Hepatic Nodules ≤20 mm in Patients with Cirrhosis.
    Zhou Y; Jing X; Zhang X; Ding J; Wang Y; Zhou H; Zhang Q; Chen Y; Yue W
    Ultrasound Med Biol; 2019 Mar; 45(3):693-701. PubMed ID: 30606633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs.
    Paisant A; Vilgrain V; Riou J; Oberti F; Sutter O; Laurent V; Rodes A; Guiu B; Cassinotto C; Trillaud H; Bricault I; Michalak S; Bruno O; Ronot M; Aubé C
    J Hepatol; 2020 May; 72(5):937-945. PubMed ID: 31870951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of gadoxetic acid-enhanced MRI and diffusion-weighted imaging in the differentiation of hypervascular hyperplastic nodule from small (<3 cm) hypervascular hepatocellular carcinoma in patients with alcoholic liver cirrhosis: A retrospective case-control study.
    Kim SS; Kim SH; Song KD; Choi SY; Heo NH
    J Magn Reson Imaging; 2020 Jan; 51(1):70-80. PubMed ID: 31062483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
    Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
    Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gadoxetic acid-enhanced magnetic resonance imaging can predict the pathologic stage of solitary hepatocellular carcinoma.
    Chou YC; Lao IH; Hsieh PL; Su YY; Mak CW; Sun DP; Sheu MJ; Kuo HT; Chen TJ; Ho CH; Kuo YT
    World J Gastroenterol; 2019 Jun; 25(21):2636-2649. PubMed ID: 31210715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of Gd-EOB-DTPA-enhanced MR imaging in characterizing cirrhotic nodules with atypical enhancement on Gd-DTPA-enhanced MR images.
    Wang YC; Chou CT; Lin CP; Chen YL; Chen YF; Chen RC
    PLoS One; 2017; 12(3):e0174594. PubMed ID: 28355258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of small (≤3 cm) hepatic lesions with atypical enhancement feature and hypointensity in hepatobiliary phase of gadoxetic acid-enhanced MRI in cirrhosis: A STARD-compliant article.
    Shin SK; Kim YS; Choi SJ; Shim YS; Jung DH; Kwon OS; Choi DJ; Kim JH
    Medicine (Baltimore); 2017 Jul; 96(29):e7278. PubMed ID: 28723741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenate dimeglumine.
    Dioguardi Burgio M; Picone D; Cabibbo G; Midiri M; Lagalla R; Brancatelli G
    Abdom Radiol (NY); 2016 Aug; 41(8):1546-54. PubMed ID: 27052455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm.
    Renzulli M; Biselli M; Brocchi S; Granito A; Vasuri F; Tovoli F; Sessagesimi E; Piscaglia F; D'Errico A; Bolondi L; Golfieri R
    Gut; 2018 Sep; 67(9):1674-1682. PubMed ID: 29437912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.